TLRY logo

TLRY

Tilray Brands, Inc.
$9.46SellTarget $4.29Report: Jan 30, 2026HealthcareDrug Manufacturers - Specialty & GenericTurnaround Candidate

Price History

Pelican View
Current$9.46-54.6%
Rec: SellConviction: Low
Entry Target
N/A
N/A
Fair Value
$4.29
(55% below current)
Stop Loss
N/A
N/A
Position Size
None
Time Horizon
N/A

Key Metrics

Market Data
52 Week High$23.20
52 Week Low$3.51
Avg. 3 Month Volume9.91M
Efficiency
LTM Gross MarginN/A
LTM EBITDA MarginN/A
LTM EBIT MarginN/A
LTM Operating MarginN/A
LTM ROAN/A
LTM ROEN/A
LTM ROICN/A
LTM ROCEN/A
Capital Structure
Market Cap (MM)$0
Enterprise Value (MM)$0
Shares OutstandingN/A
Total Debt (MM)N/A
Cash & Equivalents (MM)N/A
LTM Net Debt (MM)N/A
LTM Net Debt/EBITDAN/A
Growth
TTM Rev. GrowthN/A
Last 3-Yr Rev. CAGRN/A
Last 3-Yr EBITDA CAGRN/A
Last 3-Yr EPS CAGRN/A
Valuation
Street Target Price$8.00
LTM EV/RevenueN/A
LTM EV/Gross ProfitN/A
LTM EV/EBITN/A
LTM EV/EBITDAN/A
LTM P/EN/A
LTM EV/FCFN/A
LTM P/FCFN/A
LTM P/TBN/A
LTM P/BN/A
Dividend YieldN/A
Payout RatioN/A
About the Company

Tilray Brands, Inc. is a leading global lifestyle consumer products company operating at the nexus of cannabis, beverage, wellness, and entertainment. The company was incorporated on January 24, 2018, and is headquartered in Leamington and New York. Tilray's mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy, wellness, and create memorable experiences. The company's production platform supports over 20 brands in over 20 countries, including beverages, comprehensive cannabis offerings, and hemp-based foods. Tilray is a pioneer in cannabis research, cultivation, and distribution.

Revenue Generation

Tilray generates revenue through four reportable segments defined by the industry in which the company competes, target consumers, route to market, and margins. The segments are: 1) Cannabis operations, encompassing the production, distribution, sale, co-manufacturing, and advisory services of both medical and adult-use cannabis; 2) Beverage operations, encompassing the production, marketing, and sale of beverage products; 3) Distribution operations, encompassing the purchase and resale of pharmaceutical products to customers; and 4) Wellness products, encompassing hemp foods and cannabidiol (CBD) products. Revenue is recognized when control of promised goods is transferred to the customer or as advisory services are provided. Primary geographic markets include Canada, the United States, Europe, Australia, and Latin America. The company supplies medical cannabis to patients in over 20 countries spanning five continents.

Investment Thesis
Executive SummaryTilray Brands is a distressed cannabis-turned-CPG player attempting to mask structural operational decay through aggressive equity dilution and non-cash accounting maneuvers. While management promotes a diversified growth narrative, the reality is a company that lost $2.1 billion in fiscal 2025 and saw its tangible book value per share collapse by 42% to $4.09. Our analysis suggests the market is significantly overvaluing the company's survival prospects, ignoring a 49.4% annualized share count growth rate that hollows out per-share value.

Recent Activity

2025-12-19-9.56%
Firm: Bernstein Price Target: $10.00 Price When Posted: $12.34 Implied Downside: -19.0%
2025-11-27-21.07%
Tilray implemented a 1-for-10 reverse stock split effective December 1, 2025.
2025-11-19-6.60%
Stockholders approved director election and auditor ratification but rejected governance changes at the 2025 Annual Meeting.

Valuation Table

MethodImplied ValueWeightWeighted Value
DCF$3.8850%$1.94
Comps$4.3915%$0.66
NLV$4.8435%$1.69
Total Weighted$4.29